AD Not Linked to Early CV Risk Markers

• by Kathryn Wighton

• May 27, 2026

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

• by Kathryn Wighton

• July 16, 2026

• 2 min

Temporal trends in clinical and inflammatory features of Kawasaki disease across the COVID-19 pandemic: a single-center experience from Turkey

• by Gamze Vuran, Murat Muhtar Yılmazer

• July 15, 2026

Case Report: When crossing is not enough: restoring functional access in an extreme brachial artery loop during primary PCI

• by Ali Hakan Konuş, Recep Polat

• July 16, 2026